Renaissance Technologies
AVTX icon

Renaissance Technologies’s Avalo Therapeutics AVTX Stock Holding History

Renaissance Technologies’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Buy
120,114
+101,814
+556% +$1.59M ﹤0.01% 1957
2025
Q4 		$332K Sell
18,300
-80,400
-81% -$1.36M ﹤0.01% 2724
2025
Q3 		$1.25M Buy
+98,700
New +$849K ﹤0.01% 2371
2022
Q3 		– Sell
-118
Closed -$170K – 4014
2022
Q2 		$170K Sell
118
-9
-7% -$12K ﹤0.01% 3707
2022
Q1 		$266K Buy
127
+113
+807% +$284K ﹤0.01% 3522
2021
Q4 		$68K Buy
14
+4
+40% +$24K ﹤0.01% 3748
2021
Q3 		$61K Buy
+10
New +$81.1K ﹤0.01% 3364
2021
Q2 		– Sell
-99
Closed -$860K – 3445
2021
Q1 		$860K Buy
99
+62
+168% +$586K ﹤0.01% 2669
2020
Q4 		$284K Sell
37
-32
-46% -$222K ﹤0.01% 3052
2020
Q3 		$451K Sell
69
-99
-59% -$744K ﹤0.01% 2846
2020
Q2 		$1.26M Buy
+168
New +$1.22M ﹤0.01% 2433
2019
Q3 		– Sell
-12
Closed -$181K – 3421
2019
Q2 		$181K Buy
+12
New +$182K ﹤0.01% 3320

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies's AVTX Position: Q1 2026 in Review

Renaissance Technologies increased its Avalo Therapeutics (AVTX) stake by 556% in Q1 2026, buying an estimated $1.59M and bringing the position to 120,114 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1957.

Renaissance Technologies first reported a position in AVTX in Q2 2019 and has held it in 12 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Renaissance Technologies held 120,114 shares of Avalo Therapeutics worth $1.79M as of Q1 2026.
  • Renaissance Technologies bought 101,814 Avalo Therapeutics shares in Q1 2026, an estimated $1.59M.
  • Avalo Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1957 holding.
  • Renaissance Technologies first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 12 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.